CODX

Co-Diagnostics Inc

2.99

Jul 02 • 04:00PM ET -0.09 (-2.92%)

Healthcare Medical Devices USA Nano NASD

Jul 01, 9:05 AMCo-Diagnostics completes clinical and analytical studies for Co-Dx PCR Flu A/B & RSV point-of-care test, targets dual FDA 510(k) and CLIA Waiver submission in Q3 2026

Peers: BMRA TRIB VNRX INBS AIDX BJDX FEED NXL XAIR NUWE

Scroll to Statements

Index	-
Market Cap	11.02M
Enterprise Value	4.82M
Income	-48.50M
Sales	0.51M
Book/sh	4.45
Cash/sh	2.23
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	115
IPO	Jul 12, 2017

P/E	-
Forward P/E	-
PEG	-
P/S	21.61
P/B	0.67
P/C	1.34
P/FCF	-
EV/EBITDA	-
EV/Sales	9.45
Quick Ratio	2.09
Current Ratio	2.28
Debt/Eq	0.13
LT Debt/Eq	0.07
Option/Short	No / Yes

EPS (ttm)	-28.01
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-37.47% -
Sales past 3/5Y	-76.97% -64.54%
EPS Y/Y TTM	18.03%
Sales Y/Y TTM	-9.46%
EPS Q/Q	42.48%
Sales Q/Q	190.30%
Earnings	May 14 AMC
EPS/Sales Surpr.	- 14.87%

Insider Own	5.35%
Insider Trans	0.00%
Inst Own	7.78%
Inst Trans	3.35%
ROA	-126.56%
ROE	-151.66%
ROIC	-281.74%
Gross Margin	-187.30%
Oper. Margin	-6255.15%
Profit Margin	-9438.49%
SMA20	-22.65%
SMA50	-15.02%
SMA200	-50.51%
Trades

Shs Outstand	3.60M
Shs Float	3.49M
Short Float	3.43%
Short Ratio	0.02
Short Interest	0.12M
52W High	46.50 -93.57%
52W Low	1.26 137.30%
Volatility	21.87% 20.81%
ATR (14)	0.98
RSI (14)	43.27
Beta	2.83
Rel Volume	0.17
Avg Volume	5.76M
Volume	983,220

Perf Week	-1.97%
Perf Month	-51.93%
Perf Quarter	84.57%
Perf Half Y	-44.84%
Perf YTD	-40.89%
Perf Year	-65.15%
Perf 3Y	-91.02%
Perf 5Y	-98.79%
Perf 10Y	-
Recom	3.00
Target Price	45.00
Prev Close	3.08
Price	2.99
Change	-2.92%

Jul-01-26 09:00AM	Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test (PR Newswire)
Jun-25-26 09:00AM	Co-Diagnostics Vector Smart Division Expands Footprint to 21 States (PR Newswire) -14.57%
Jun-18-26 09:05AM	Co-Diagnostics Hosts Kingdom of Saudi Arabia Joint Venture CoMira for Unveiling of Future Automated Manufacturing Line (PR Newswire)
Jun-11-26 09:00AM	Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx PCR Pro with Mexico Distributor Agreement (PR Newswire)
Jun-02-26 09:00AM	Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx PCR Point-of-Care Platform Capabilities (PR Newswire)
01:00PM	Loading…
May-26-26 01:00PM	CODX Stock Explodes Over 630% In Six Sessions Retail Traders Bet The Rally Isnt Over Yet (Stocktwits) +79.68%
09:00AM	Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara (PR Newswire)
May-19-26 10:54PM	Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) +43.80% +21.32%
10:34AM	Co-Diagnostics Develops Ebola Assay Strategy Following WHO Emergency Alert (CODX) (InvestorsHub)
May-15-26 08:30AM	Co-Diagnostics, Inc. Q1 2026 Earnings Call Summary (Moby) -21.17%
01:02AM	Co-Diagnostics Inc (CODX) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial ... (GuruFocus.com)
May-14-26 04:01PM	Co-Diagnostics Reports First Quarter 2026 Financial Results (PR Newswire)
May-11-26 05:43AM	CoMira concludes lease agreement for plant in Sudair Industrial City, Saudi Arabia (Medical Device Network) -24.90%
May-08-26 09:00AM	Co-Diagnostics Joint Venture CoMira Finalizes Lease Agreement for Manufacturing Facility in Saudi Arabia's Sudair Industrial City (PR Newswire) +31.09%
Apr-16-26 09:00AM	Co-Diagnostics Invited to Present at Stop TB Partnership Summit in Washington, D.C. (PR Newswire)
09:00AM	Loading…
Apr-14-26 09:00AM	Co-Diagnostics to Showcase Co-Dx PCR Platform and CE-IVD Solutions at ESCMID 2026 in Munich, Germany (PR Newswire)
Apr-09-26 09:00AM	Co-Diagnostics Executives to Participate in European Trade Mission with Utah Governor and WTC Utah (PR Newswire)
Apr-02-26 09:00AM	Co-Diagnostics Joint Venture CoMira Receives Approval for Manufacturing Facility in Kingdom of Saudi Arabia's Sudair Industrial City (PR Newswire)
Apr-01-26 08:30AM	Co-Diagnostics, Inc. Q4 2025 Earnings Call Summary (Moby) -12.90%
Mar-31-26 11:02PM	Co-Diagnostics Inc (CODX) Q4 2025 Earnings Call Highlights: Strategic Expansions and Financial ... (GuruFocus.com) +9.41%
04:01PM	Co-Diagnostics Reports Full Year 2025 Financial Results (PR Newswire)
Mar-25-26 08:00AM	Co-Diagnostics Ships Diagnostic Materials to India for Initiation of Tuberculosis Clinical Studies Following Recently Issued Guidance from the World Health Organization (PR Newswire) -13.22%
Mar-20-26 03:30PM	Co-Diagnostics (CODX) Expands CoSara Distribution Territory Across South Asia (NewMediaWire)

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

ChairmanMr. Dwight H. Egan

PresidentMr. Richard David Abbott

CFO & Company SecretaryMr. Brian L. Brown CPA

Chief Operating OfficerMr. David Nielsen

Vice President of Finance & AccountingMr. Dan Bohrer CPA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

CODX

Co-Diagnostics Inc

Upgrade your Finviz experience